title: Update in thrombosis: answers to perplexing questions.
abstract: Recent clinical trials are answering some of the perplexing clinical questions about venous thromboembolism (VTE), such as the length and intensity of anticoagulation needed to prevent recurrence. We review some of these clinical trials and their implications for physicians and patients.
authors.affiliation: Department of Medicine, Section of General Medicine, Firm Chief, VA Connecticut Health Care System, West Haven, CT, USA. daniel.federman@med.va.gov
authors.forename: Daniel G
authors.initials: DG
authors.lastname: Federman
authors.forename: Gina R
authors.initials: GR
authors.lastname: Brescia
authors.forename: John P
authors.initials: JP
authors.lastname: Moriarty
authors.forename: Sally G
authors.initials: SG
authors.lastname: Haskell
authors.forename: Raj
authors.initials: R
authors.lastname: Krishnamurthy
authors.forename: Robert S
authors.initials: RS
authors.lastname: Kirsner
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005165:Factor V; D006801:Humans; D012307:Risk Factors; D055502:Secondary Prevention; D013923:Thromboembolism / Q000188:drug therapy* / Q000235:genetics; D020246:Venous Thrombosis / Q000188:drug therapy* / Q000235:genetics; D014859:Warfarin / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000925:Anticoagulants; C095381:factor V Leiden; D014859:Warfarin; D005165:Factor V